Growth and Expansion PharmaForce recently expanded its facilities in Hilliard and New Albany, Ohio, indicating strong growth momentum and an increased production capacity that could require additional supporting technologies, supply chain solutions, or specialized manufacturing equipment.

Market Specialization Focusing on sterile injectable products positions PharmaForce as a key player in a highly regulated and competitive segment, presenting opportunities for partnerships in quality assurance, sterile manufacturing technologies, and regulatory consulting.

Financial Scale With annual revenues between 25 million and 50 million dollars, PharmaForce offers a significant market opportunity for mid-sized suppliers of pharmaceutical ingredients, packaging, lab analytics, and other supporting services tailored for manufacturing firms of this size.

Parent Company Support Being wholly owned by Luitpold Pharmaceuticals, a Daiichi Sankyo Group company, provides access to broader industry expertise, innovation networks, and potential joint ventures or licensing opportunities within a global pharmaceutical group.

Industry Positioning Compared to larger contract providers like IQVIA and Syneos Health, PharmaForce’s focused local operations in Ohio present opportunities for targeted regional partnerships, supply chain optimization, and niche service offerings in sterile injectable manufacturing.